David Tsai Ting

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.

This study identifies Pdgfd-Pdgfrb signaling as a driver of perineural invasion in pancreatic cancer by promoting cancer cell invasiveness and nerve engagement.

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

This study uses spatial transcriptomics to show that IPMN subtypes form a molecular continuum originating from gastric-type cells, with repeat element expression linked to disease progression.

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

This study uses single cell spatial transcriptomics to show LINE1 repeat RNA expression in HCC correlates with a disorganized immune microenvironment and poor patient survival.

This study uses single-nucleus and spatial transcriptomics to analyze pancreatic cancer before and after neoadjuvant treatment, revealing changes in cell states and immune infiltration that may inform therapy.